Liver Disease
In Focus
Navigating NAFLD: Unveiling the approach to mitigate the impact of NAFLD
According to the Centers for Disease Control and Prevention, there have been substantial increases in liver-related deaths over the last two...
Latest News
Naltrexone is safe and beneficial in AUD with cirrhosis
VIENNA –
From the AGA Journals
Incidental hepatic steatosis
It is important to identify patients at risk of progressive fibrosis.
Conference Coverage
Breakthroughs and challenges in hepatology
“I have witnessed some of the miracles in modern medicine. However, there remain many challenges.’
Latest News
FDA rejects NASH drug for the second time
Intercept first sought FDA approval for OCA in 2019. The company will discontinue all NASH-related investment.
Latest News
‘Exciting time for NASH’ with resmetirom phase 3 results
Two doses of resmetirom met the primary endpoints of NASH resolution and no worsening of fibrosis on liver biopsy.
Conference Coverage
What is new in hepatology in 2023?
There has been a paradigm shift in risk stratification of cirrhosis and targets for prevention and treatment of decompensation.
News from the FDA/CDC
FDA advisory committee votes against approval for NASH drug
“Typically, in clinical practice, NASH patients are followed every 6-12 months, so more frequent monitoring would be a substantial change and may...
Conference Coverage
Analysis: 40% of information about cirrhosis on TikTok is incorrect
Study presented at DDW finds that patient-derived sources are usually trustworthy, promotional sources are often misleading.
Latest News
Harnessing ChatGPT to improve liver disease outcomes
ChatGPT information is correct, but inadequate.